Season 2 - Ep. 5: LAA occlusion - Chronic thromboembolic pulmonary hypertension

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies

LAA occlusion

Chronic thromboembolic pulmonary hypertension

Mythbusters: Do cholesterol lowering drugs provoke dementia?

Host: Perry Elliott

Guests: Carlos Aguiar, Stephan Rosenkranz, Jacqueline Saw

Want to watch that episode? Go to: https://esc365.escardio.org/event/1140

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.

Stephan Rosenkranz has declared to have potential conflicts of interest to report: speaker fees and consultation for Bayer, MSD, Boehringer-Ingelheim and Inari.

Jacqueline Saw has declared to have potential conflicts of interest to report: proctor and consultancy fees from Abbott and Boston Scientific.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.